PFE
Pfizer
$25.08
▼ 0.5%Updated Today 7:15 PM ET
▲ Up 5.6% over the last 12 months
Market Cap
$143.68B
P/E
19.13x
Forward P/E (est.)
20.19x
ROE
8.4%
Revenue Growth
1.4%
EPS Growth
-5.3%
Profit Margin
11.8%
FCF Yield
11.2%
Debt / Equity
0.75x
ROIC
—
Interest Coverage
—
Current Ratio
1.25x
Dividend Yield
6.6%
Implied Growth (rev. DCF)
2.5%
Rating Score
48/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what PFE's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. PFE trades near $25.08, below its 50-day average ($26.25) and 200-day average ($25.88). Price below both averages is a downtrend — momentum is against buyers for now.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 37 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. PFE's is $0.53 (~2.1% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month PFE found buyers near $24.94 (support) and sellers near $26.54 (resistance); its 52-week range is $23.11–$28.75. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 3.2× the 20-day average — heavier than usual, which adds conviction to the move. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Pfizer (PFE) is a large-cap company in the Pharmaceuticals industry, part of the Health Care sector of the S&P 500, with a market value around $143.68B.
In its latest reported year it generated about $62.58B in revenue and $7.77B in net profit.
Our model rates PFE Neutral (48/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
-6.3%
Revenue moved from $81.29B in 2021 to $62.58B in 2025, a -6.3% compound annual growth rate. The most recent year was roughly flat (1.4%) year over year. Slower, mature growth is common for established businesses.
Gross Margin
74.8%
Operating Margin
15.4%
Net Margin
12.4%
ROE
8.4%
Pfizer keeps about 11.8% of each sales dollar as net profit, with a 74.8% gross margin and 15.4% operating margin. Return on equity is 8.4%. Margins are moderate — typical of a competitive but profitable business.
Total Debt
$4.00B
Net Debt
$2.30B
Net Debt / EBITDA
—
Debt / Equity
0.75x
Leverage: debt-to-equity is 0.7x, with a current ratio of 1.3x. That is a moderate, manageable debt load for most businesses. It carries roughly $4.00B of total debt against $1.70B of cash.
Operating CF
$11.70B
Free Cash Flow
$9.07B
FCF Margin
14.5%
In the latest year Pfizer produced about $11.70B of operating cash flow and $9.07B of free cash flow after capital spending. That is a free-cash-flow yield of about 11.2% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
P/E
19.13x
P/S
2.36x
P/B
1.58x
EV / EBITDA
—
PFE trades at 19.1x trailing earnings (about 20.2x on estimated forward earnings), 2.4x sales, and 1.6x book value. Reverse-engineering today's price implies the market expects roughly 2.5% long-term free-cash-flow growth. That is a fairly typical valuation for a profitable company.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How PFE stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), PFE ranks #40 of 59 by our overall rating. It trades at a discount versus the sector on earnings (19.1x P/E vs. 25.4x median) with a lower return on equity (8.4% vs. 14.9%) and slower revenue growth (1.4% vs. 7.9%).
P/E vs sector
19.1x
median 25.4x
ROE vs sector
8.4%
median 14.9%
Growth vs sector
1.4%
median 7.9%
Sector rank
#40
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$16.80 – $29.02
vs. $25.08 today · expected CAGR -8% – 3%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $64.46B | $66.39B | $68.38B | $70.43B | $72.55B |
| Net income | $7.73B | $7.97B | $8.21B | $8.45B | $8.71B |
| EPS | $1.36 | $1.40 | $1.44 | $1.48 | $1.53 |
| Share price (low) | $14.93 | $15.38 | $15.84 | $16.31 | $16.80 |
| Share price (high) | $25.79 | $26.56 | $27.36 | $28.18 | $29.02 |
| CAGR (low–high) | -40% / 3% | -22% / 3% | -14% / 3% | -10% / 3% | -8% / 3% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for PFE:
- Healthy free-cash-flow yield (~11.2%) funds buybacks and dividends.
- Pays a 6.6% dividend on top of any price gains.
The case against PFE:
- Revenue growth is slow (1.4%), limiting the upside engine.
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Growth risk — sluggish revenue (1.4%) leaves little margin for execution missteps.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Pfizer is a large-cap health care business growing at a mature pace, with modest profitability, and a heavier debt load to watch. It trades at 19.1x earnings, which our model scores Neutral (48/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.